IL123642A - Pharmaceutical compositions comprising mononuclear phagocytes to promote axonal regeneration - Google Patents

Pharmaceutical compositions comprising mononuclear phagocytes to promote axonal regeneration

Info

Publication number
IL123642A
IL123642A IL12364296A IL12364296A IL123642A IL 123642 A IL123642 A IL 123642A IL 12364296 A IL12364296 A IL 12364296A IL 12364296 A IL12364296 A IL 12364296A IL 123642 A IL123642 A IL 123642A
Authority
IL
Israel
Prior art keywords
mononuclear phagocytes
axonal regeneration
pharmaceutical compositions
mammal
methods
Prior art date
Application number
IL12364296A
Other languages
English (en)
Other versions
IL123642A0 (en
Inventor
Michal Eisenbach-Schwartz
Orly Spiegler
David L Hirschberg
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Publication of IL123642A0 publication Critical patent/IL123642A0/xx
Publication of IL123642A publication Critical patent/IL123642A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/17—Monocytes; Macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/414—Nervous system antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/08—Coculture with; Conditioned medium produced by cells of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • External Artificial Organs (AREA)
  • Thermotherapy And Cooling Therapy Devices (AREA)
  • Secondary Cells (AREA)
IL12364296A 1995-09-15 1996-09-12 Pharmaceutical compositions comprising mononuclear phagocytes to promote axonal regeneration IL123642A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US52884595A 1995-09-15 1995-09-15
US08/695,351 US5800812A (en) 1995-09-15 1996-08-09 Methods of use of mononuclear phagocytes to promote axonal regeneration
PCT/US1996/014578 WO1997009885A1 (en) 1995-09-15 1996-09-12 Compositions and methods of use of mononuclear phagocytes to promote axonal regeneration

Publications (2)

Publication Number Publication Date
IL123642A0 IL123642A0 (en) 1998-10-30
IL123642A true IL123642A (en) 2005-08-31

Family

ID=27062850

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12364296A IL123642A (en) 1995-09-15 1996-09-12 Pharmaceutical compositions comprising mononuclear phagocytes to promote axonal regeneration

Country Status (13)

Country Link
US (2) US5800812A (de)
EP (1) EP0952772B1 (de)
JP (1) JP4100707B2 (de)
AT (1) ATE290789T1 (de)
AU (1) AU714205B2 (de)
CA (1) CA2232262A1 (de)
DE (1) DE69634499T2 (de)
DK (1) DK0952772T3 (de)
ES (1) ES2241002T3 (de)
IL (1) IL123642A (de)
NZ (1) NZ319365A (de)
PT (1) PT952772E (de)
WO (1) WO1997009885A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267955B1 (en) * 1995-09-15 2001-07-31 Yeda Research And Development Co. Ltd. Mononuclear phagocytes and their use to promote axonal regeneration
US7795202B2 (en) * 1997-08-04 2010-09-14 Neurorepair, Inc. Methods for treating a neurological disorder by peripheral administration of a transforming growth factor alpha (TGF-a)
US20010007657A1 (en) * 1997-08-04 2001-07-12 Reid James Steven Compositions and methods for manipulating glial progenitor cells and treating neurological deficits
CA2298506A1 (en) * 1997-08-04 1999-02-11 The Regents Of The University Of California Methods for treating neurological deficits
CA2328612A1 (en) * 1998-05-19 1999-11-25 Yeda Research And Development Co., Ltd. Activated t cells, nervous system-specific antigens and their uses
SE9802264D0 (sv) 1998-06-25 1998-06-25 Neuronova Ab A method of isolating cells
US6541247B1 (en) 1998-06-25 2003-04-01 Neuronova Ab Method of isolating ependymal neural stem cells
IL125983A0 (en) * 1998-08-30 1999-04-11 Yeda Res & Dev Pharmaceutical composition comprising factor xiiia
ATE422901T1 (de) * 2001-03-12 2009-03-15 Inst Of Gene And Brain Science Granulocyte-macrophage colony-stimulating factor (gm-csf) als heilmittel für nervenschäden
AU2002353465B2 (en) * 2001-11-21 2008-10-16 Yeda Research And Development Co. Ltd. Process for the manufacture of human mononuclear phagocytic leukocytes
WO2003105750A2 (en) * 2002-06-14 2003-12-24 Yeda Research And Development Co. Ltd Antigen-presenting cells for neuroprotection and nerve regeneration
US20090010873A1 (en) * 2004-11-29 2009-01-08 Yeda Research And Development Co. Ltd. Methods of Cell Therapy, Neurogenesis and Oligodendrogenesis
BRPI0919020B8 (pt) * 2008-09-12 2021-05-25 Cryopraxis Criobiologia Ltda uso de células de linhagem monocitária enriquecidas para tratar isquemia e para tratar angina pectoris
EP2790712B1 (de) 2011-12-14 2016-08-31 Yeda Research and Development Co. Ltd. Menschliche monocytensubpopulation zur behandlung von verletzungen des zentralen nervensystems
CN105377273A (zh) 2013-05-22 2016-03-02 耶达研究与发展公司 用于治疗眼睛疾病或病症的人类单核细胞亚群
EP3615568A4 (de) * 2017-04-25 2021-01-20 Purdue Research Foundation Dreidimensionaler (3d) gewebegezüchteter muskel zur geweberestauration
EP4096635A4 (de) 2020-01-27 2024-02-21 GeniPhys, Inc. Biologischer füllstoff zur wiederherstellung und regeneration von gewebe

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5157024A (en) * 1977-10-16 1992-10-20 Strategic Medical Research Corporation Method of enhancing the activity of phagocytes including macrophages, modulating the cellular or humoral immune response, and reducing the adverse effects of stress in warm blooded animals
IL71440A0 (en) * 1984-04-04 1984-07-31 Univ Ramot Composition for nerve regeneration
US5078996A (en) * 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
US5082670A (en) * 1988-12-15 1992-01-21 The Regents Of The University Of California Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system
IL97365A0 (en) * 1991-02-27 1992-05-25 Yeda Res & Dev Pharmaceutical compositions comprising a lymphokine
IL91459A0 (en) * 1989-08-28 1990-04-29 Yeda Res & Dev Oligodendrocyte inhibitory factor

Also Published As

Publication number Publication date
AU714205B2 (en) 1999-12-23
ES2241002T3 (es) 2005-10-16
WO1997009885A1 (en) 1997-03-20
NZ319365A (en) 1999-08-30
DE69634499T2 (de) 2006-01-05
CA2232262A1 (en) 1997-03-20
EP0952772A4 (de) 2002-01-02
JPH11513370A (ja) 1999-11-16
ATE290789T1 (de) 2005-04-15
PT952772E (pt) 2005-07-29
EP0952772B1 (de) 2005-03-16
EP0952772A1 (de) 1999-11-03
DE69634499D1 (de) 2005-04-21
AU7157296A (en) 1997-04-01
US5800812A (en) 1998-09-01
DK0952772T3 (da) 2005-07-18
IL123642A0 (en) 1998-10-30
US6117424A (en) 2000-09-12
JP4100707B2 (ja) 2008-06-11

Similar Documents

Publication Publication Date Title
IL123642A (en) Pharmaceutical compositions comprising mononuclear phagocytes to promote axonal regeneration
WO1999046366A8 (en) Uses for humane non-autologous mesenchymal stem cells
MX348062B (es) Mutantes que degradan proteoglicanos para tratamiento del snc.
HUS1400034I1 (hu) Dialkil-fumarátok alkalmazása autoimmun betegségek kezelésére szolgáló gyógyászati készítmények elõállítására
AU2782499A (en) Isolated stromal cells for use in the treatment of diseases of the central nervous system
MY122383A (en) Cyclic boroproline compounds
WO1998020932A3 (en) Conditioning for allogeneic stem cell transplantation
WO1996025947A3 (en) Induction of e-selectin for targetting therapeutic agents
DE69333775D1 (de) Synthetische katalytische freie radikalfänger, verwendbar als antioxidantien zur prävention und therapie von krankheiten
DE69615561D1 (de) Polyether-blockcopolymer micellare zusammensetzungen zur zielgerichteten verabreichung biologischer stoffe
Plaut et al. Increase in histamine receptors on thymus-derived effector lymphocytes during the primary immune response to alloantigens
IL157841A0 (en) Activation of natural killer cells by adenosine a3 receptor agonists
DE69635924D1 (de) Isolierung und züchtung von schwannzellen
NZ505834A (en) Compositions containing polypeptides isolated from mycobacterium vaccae and methods for their use
BR9612821A (pt) Métodos para a prevenção de rejeição de enxerto em transplante e para a produção de uma célula de hospedeiro para terapia genética universal
FI962550A0 (fi) Deuterisoidut vaikuttavat aineet transdermaalisessa käyttötarkoituksessa
PT768886E (pt) Efeitos de revestimento endotelial e tratamento de desordens vasospasticas
MXPA02011592A (es) Composiciones de celulas dendriticas circulantes, humanas y metodos.
Mielcarek et al. Denileukin diftitox as prophylaxis against graft-versus-host disease in the canine hematopoietic cell transplantation model
EP1637146A3 (de) Ex vivo behandlung von allogenen und xenogenen t-zellen mit gp39-antagonisten
EP1152767B1 (de) Verfahren zur herstellung antitumoraler th1-zellen
ATE263833T1 (de) Verwendung von dendritischen zellen-depletierten zusammensetzungen zur verbesserung der transplantation von allogenen hämatopoietischen zellen
FI941451A0 (fi) Entsymaattisesti valmistettu dimeerinen IL-2 ja sen valmistuksessa käytettävä, hermoista johdettu transglutaminaasi
UA32157A (uk) Спосіб лікування діабетичної ретинопатії
IT1274592B (it) Composizione farmaceutica per la terapia tumorale contenente xenoantigeni

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees